IL2 Chimeric Constructs Targeting Oxidized Lipids
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current IL2 therapies lack specificity, leading to 'off-target' effects due to the ubiquitous presence of lymphocyte populations activated by IL-2, and there is a need to enhance local concentrations at inflammatory tissues to improve treatment efficacy for autoimmune and inflammatory diseases.
Innovation Solution
Development of chimeric constructs comprising an IL2 moiety fused with a targeting moiety that binds to oxidized proteins or lipids, specifically targeting inflammatory tissues, such as those with oxidation-specific epitopes, using antibodies or antibody fragments like E06 scFv, to increase Treg recruitment and proliferation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If IL2 is used as a therapeutic to boost immune responses, then immune responses are enhanced, but off-target effects occur due to ubiquitous presence of lymphocyte populations
Solution Approach 1:
The patent applies local quality by creating chimeric IL2 constructs with tissue-specific targeting moieties that direct the therapeutic activity to specific inflamed tissues rather than distributing it systemically. The targeting moiety confers localized binding properties to the IL2 molecule, enabling it to selectively interact with cells in inflamed tissues while sparing other lymphocyte populations throughout the body.
Solution Approach 2:
The patent uses an intermediary approach by introducing a targeting moiety as a mediator between the IL2 therapeutic and its target cells in inflamed tissues. This targeting moiety acts as a bridge that directs IL2 specifically to the desired location, preventing direct interaction with non-target lymphocyte populations and thereby reducing off-target effects.
2Reliability
If IL2 is administered systemically to treat autoimmune diseases, then regulatory T cells increase and clinical improvement occurs, but treatment efficacy is limited by low local concentrations at the tissue of interest
Solution Approach 1:
The chimeric IL2 constructs incorporate targeting moieties that provide local quality by directing the therapeutic to specific inflamed tissues. This localization ensures that high concentrations of IL2 are delivered precisely where needed, rather than relying on systemic distribution which results in low local concentrations at the tissue of interest.
3Object-generated harmful factors
If targeting moiety is added to IL2 to provide tissue specificity, then off-target effects are reduced, but device complexity increases
Solution Approach 1:
The patent employs composite materials by creating chimeric proteins that combine the IL2 therapeutic moiety with a targeting moiety into a single integrated construct. This composite structure allows the molecule to perform multiple functions (immune stimulation and tissue targeting) simultaneously, reducing off-target effects without requiring separate administration of multiple agents.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The targeted chimeric constructs significantly enhance Treg recruitment and proliferation at inflammatory sites, reducing 'off-target' effects and improving clinical outcomes by maintaining biological activity while minimizing activation of effector cells.
Implementation Method 1
the targeting moiety binds to an oxidized protein or oxidized lipid, such as a pro-inflammatory oxidized protein or oxidized lipid
Data Source
AI summary
The present invention relates to a targeted chimeric construct, comprising i) an interleukin 2 (IL2) moiety and ii) a targeting moiety which binds to an oxidized protein or oxidized lipid. The targeting moiety is preferably an antibody or scFv binding specific oxidized proteins or oxidized lipids and targets the fusion protein to inflammatory tissues. The chimeric construct preferably further comprises a beta chain of the C4b-binding protein (C4BP), which is capable of forming a dimeric protein.